Compounds and compositions as protein kinase inhibitors

Details Compounds and compositions as protein kinase inhibitors Compounds and compositions as protein kinase inhibitors

2004-10-08

2008-11-11

Seaman, D. Margaret (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S157000, C546S123000, C544S224000, C514S264100, C514S299000

Reexamination Certificate

active

07449582

ABSTRACT:
The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of the Abl, BCR-Abl, CSK, JNK1, JNK2, PDGF-R, p38, p70S6K, TGFβ, SRC, EGFR, c-Kit, trkB, FGFR3, Fes, Lck, Syk, RAF, MKK4, MKK6 and SAPK2β kinases.

REFERENCES:
patent: 6506749 (2003-01-01), Chen et al.
patent: 6518276 (2003-02-01), Arzeno et al.
patent: 6753427 (2004-06-01), Arzeno et al.
patent: 6849409 (2005-02-01), Schubart et al.
patent: 6861423 (2005-03-01), Chen et al.
patent: WO 2002/28853 (2002-04-01), None
Clozel et al., Pharmacology of the Urotensin-II Receptor Antagonist Palosuran (ACT-058362; 1-[2-(4-Benzyl-4-hydroxy-piperidin-1-yl)-ethyl]-3-(2-methyl-quinolin-4-yl)-urea Sulfate Salt): First Demonstration of a Pathophysiological Role of the Eurotensin System, The Journal of Pharmacology and Experimental Therapeutics, 2004, pp. 204-212, The American Society for Pharmacology and Experimental Therapeutics.

Affiliated with

Also associated with

Rating

Compounds and compositions as protein kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds and compositions as protein kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds and compositions as protein kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4027475